Another Reason for Dislike

These 10% moves are a little ridiculous these days. I have to tell you that the 10% move today in Bristol-Myers (BMY) was about as ridiculous as I have ever seen.

Yes, the big call on a big anti-Hep C drug might be off the table and investors have a fascination for anything that can beat Hep C. Bristol paid a couple of billion for a company that's working on one, so I get the disappointment. Plus, I have no doubt there will be more selling tomorrow because these 10% affairs have ALMOST ALWAYS brought out more sellers the next day. But at the same time, the yield is safe and the company's got a lot of irons in the fire as we said in the e-mails we sent out today before we bought the stock for Action Alerts PLUS....400 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.